Literature DB >> 10456690

Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives.

M V Bach1, R T Coutts, G B Baker.   

Abstract

1. Amphetamine (AM) and five amphetamine derivatives, N-ethylamphetamine (NEA), N-butylamphetamine (NBA), 4-methoxyamphetamine (M-AM), 4-methoxy-N-ethylamphetamine (M-NEA) and 4-methoxy-N-butylamphetamine (M-NBA) were incubated with microsomal preparations from cells expressing human CYP2D6 to determine whether the enzyme was capable of catalyzing the direct ring oxidation of all substrates; the N-dealkylation of NEA, NBA, M-NEA and M-NBA; and the O-demethylation of M-AM, M-NEA and M-NBA. 2. None of the six compounds examined was N-dealkylated to any extent. 3. The only metabolites produced from AM, NEA and NBA were the corresponding ring 4-hydroxylated compounds, and the rates of formation were low. 4. All ring 4-methoxylated substrates were efficiently O-demethylated by CYP2D6 to their corresponding phenols. The size of the N-alkyl group influenced the rates of formation of these phenolamines. In contrast to reported findings with 2- and 3-methoxyamphetamines, none of the 4-methoxyamphetamines was ring-oxidized in the CYP2D6 enzyme system to 2- or 3-hydroxy-4-methoxyamphetamines or to dihydroxyamphetamines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10456690     DOI: 10.1080/004982599238344

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  16 in total

1.  Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism.

Authors:  Rayomand J Unwalla; Jason B Cross; Sumeet Salaniwal; Adam D Shilling; Louis Leung; John Kao; Christine Humblet
Journal:  J Comput Aided Mol Des       Date:  2010-04-02       Impact factor: 3.686

2.  Sustained release d-amphetamine reduces cocaine but not 'speedball'-seeking in buprenorphine-maintained volunteers: a test of dual-agonist pharmacotherapy for cocaine/heroin polydrug abusers.

Authors:  Mark K Greenwald; Leslie H Lundahl; Caren L Steinmiller
Journal:  Neuropsychopharmacology       Date:  2010-09-29       Impact factor: 7.853

3.  N-Methyl-1-(4-methoxyphenyl)-2-aminopropane (PMMA) and N-Methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDMA) produce non-identical discriminative stimuli in rats.

Authors:  Richard A Glennon; Richard Young; Małgorzata Dukat; Jean Chang-Fong; Mohamed El-Zahabi
Journal:  Pharmacol Biochem Behav       Date:  2007-01-18       Impact factor: 3.533

Review 4.  Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.

Authors:  J S Markowitz; K S Patrick
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  PKCδ knockout mice are protected from para-methoxymethamphetamine-induced mitochondrial stress and associated neurotoxicity in the striatum of mice.

Authors:  Eun-Joo Shin; Duy-Khanh Dang; Hai-Quyen Tran; Yunsung Nam; Ji Hoon Jeong; Young Hun Lee; Kyung Tae Park; Yong Sup Lee; Choon-Gon Jang; Jau-Shyong Hong; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Neurochem Int       Date:  2016-09-10       Impact factor: 3.921

6.  A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults.

Authors:  Jessica K Roberts; Sarah F Cook; Chris Stockmann; Douglas E Rollins; Diana G Wilkins; Catherine M T Sherwin
Journal:  Clin Drug Investig       Date:  2015-10       Impact factor: 2.859

Review 7.  Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.

Authors:  Rafael de la Torre; Magí Farré; Mónica Navarro; Roberta Pacifici; Piergiorgio Zuccaro; Simona Pichini
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?

Authors:  Rafael de la Torre; Samanta Yubero-Lahoz; Ricardo Pardo-Lozano; Magí Farré
Journal:  Front Genet       Date:  2012-11-12       Impact factor: 4.599

9.  Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate.

Authors:  Benno Roesch; Mary E Corcoran; Jennifer Fetterolf; Mary Haffey; Patrick Martin; Peter Preston; Jaideep Purkayastha; Phillip Wang; James Ermer
Journal:  Drugs R D       Date:  2013-06

10.  An open-label investigation of the pharmacokinetic profiles of lisdexamfetamine dimesylate and venlafaxine extended-release, administered alone and in combination, in healthy adults.

Authors:  James Ermer; Mary B Haffey; Cynthia Richards; Kenneth Lasseter; Benno Roesch; Jaideep Purkayastha; Mary Corcoran; Bree Harlin; Patrick Martin
Journal:  Clin Drug Investig       Date:  2013-04       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.